From ImmunoToxins to ImmunoRNases

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|9|3|210-214

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.9, Iss.3, 2008-06, pp. : 210-214

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ribonucleases and ImmunoRNases as Anticancer Drugs

By  

Current Pharmaceutical Design, Vol. 15, Iss. 23, 2009-01 ,pp. : 2665-2675

Bentham Science Publishers

Access to resources Recommend Favorite

Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy

By  

Current Pharmaceutical Biotechnology, Vol. 9, Iss. 3, 2008-06 ,pp. : 231-234

Bentham Science Publishers

Access to resources Recommend Favorite

Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 23, 2012-01 ,pp. : 2642-2654

Bentham Science Publishers

Access to resources Recommend Favorite

IO Nation: The Rise of Immuno-Oncology

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 12, Iss. 3, 2015-03 ,pp. : 176-181

Bentham Science Publishers

Access to resources Recommend Favorite

Immuno-Isolation in Oncology - A Mini-Review

By  

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 3, 2001-09 ,pp. : 269-277

Bentham Science Publishers

Access to resources Recommend Favorite